Editorial
What do we learn from HER2-positive breast cancer genomic profiles?
-
Correspondence: Charles Theillet charles.theillet@inserm.fr
IRCM, INSERM U896, CRLC Val d'Aurelle, F34298 Montpellier, France
Breast Cancer Research 2010, 12:107 doi:10.1186/bcr2571
See related research article by Staaf et al., http://breast-cancer-research.com/content/12/3/R25
Published: 1 June 2010Abstract
Patients with a tumor presenting amplification of the HER2 gene are currently proposed trastuzumab (herceptin) and this has greatly changed their outcome. However, a number of HER2-positive cancers show intrinsic or acquired resistance to trastuzumab and there are clear indications that they form a heterogeneous group of tumors. A paper in this issue of Breast Cancer Research addresses this heterogeneity at the genomic level.